ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly total research and development expense ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations & Segment Footnote
Latest, Q2 2026
3,819
Period ended Jun 30, 2026
Change on a year earlier
+14.5%
3,336 in Q2 2025
History
69 quarters
Since Q2 2008
Sources
52
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total research and development expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,819 | +14.5% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,510 | +28.4% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,802 | +25.8% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,466 | +26.8% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,336 | +23.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,734 | +8.4% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,023 | +18.0% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,734 | +13.5% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,711 | +15.1% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,523 | +27.1% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,562 | +28.4% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 2,409 | +33.6% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 2,357 | +32.2% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,985 | +23.3% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,996 | +5.1% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,803 | +5.7% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,782 | +7.7% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,610 | -3.7% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,898 | +9.8% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,705 | +16.4% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,655 | +19.0% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,672 | +20.1% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,729 | +9.3% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,465 | +6.1% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,390 | -0.9% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,392 | +13.1% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,581 | +13.6% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,381 | +7.8% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,402 | +10.3% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,231 | +11.1% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,392 | +13.5% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,281 | -4.4% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,271 | -0.1% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,108 | -12.0% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,226 | -19.2% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,340 | +8.4% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,272 | -4.8% | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,258 | +3.1% | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,517 | +5.0% | Form 10-K (filed 2019-02-19) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,236 | +8.1% | Form 10-Q (filed 2016-10-28) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,336 | +14.2% | Form 10-Q (filed 2016-07-28) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,221 | +17.5% | Form 10-Q (filed 2016-04-29) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,444 | +21.8% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,143 | -8.0% | Form 10-Q (filed 2015-10-30) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,170 | -2.2% | Form 10-Q (filed 2015-07-30) ↗ |
| Q1 2015 | Mar 31, 2015 | 1,039 | -6.3% | Form 10-Q (filed 2015-04-30) ↗ |
| Q4 2014 | Dec 31, 2014 | 1,186 | – | Form 10-K (filed 2015-02-19) ↗ |
| Q3 2014 | Sep 30, 2014 | 1,243 | – | Form 10-Q (filed 2014-10-29) ↗ |
| Q2 2014 | Jun 30, 2014 | 1,195 | -10.1% | Form 10-Q (filed 2014-07-28) ↗ |
| Q1 2014 | Mar 31, 2014 | 1,109 | -17.7% | Form 10-Q (filed 2014-04-28) ↗ |
| Q2 2013 | Jun 30, 2013 | 1,330 | +0.7% | Form 10-Q (filed 2013-07-26) ↗ |
| Q1 2013 | Mar 31, 2013 | 1,348 | +17.1% | Form 10-Q (filed 2013-04-26) ↗ |
| Q4 2012 | Dec 31, 2012 | 1,463 | – | Form 10-K (filed 2013-02-21) ↗ |
| Q3 2012 | Sep 30, 2012 | 1,343 | -47.2% | Form 10-Q (filed 2012-10-26) ↗ |
| Q2 2012 | Jun 30, 2012 | 1,321 | – | Form 10-Q (filed 2012-07-27) ↗ |
| Q1 2012 | Mar 31, 2012 | 1,152 | +2.4% | Form 10-Q (filed 2012-04-30) ↗ |
| Q2 2011 | Sep 30, 2011 | 2,542 | +108.4% | Form 10-Q (filed 2011-10-28) ↗ |
| Q1 2011 | Mar 31, 2011 | 1,124 | +8.2% | Form 10-Q (filed 2011-04-29) ↗ |
| Q4 2010 | Dec 31, 2010 | 1,438 | +18.2% | Form 10-K (filed 2011-02-22) ↗ |
| Q3 2010 | Sep 30, 2010 | 1,220 | +8.7% | Form 10-Q (filed 2010-10-29) ↗ |
| Q2 2010 | Jun 30, 2010 | 1,187 | +14.1% | Form 10-Q/A (filed 2010-08-02) ↗ |
| Q1 2010 | Mar 31, 2010 | 1,039 | +9.7% | Form 10-Q (filed 2010-04-30) ↗ |
| Q4 2009 | Dec 31, 2009 | 1,217 | +14.9% | Form 10-K (filed 2010-02-22) ↗ |
| Q3 2009 | Sep 30, 2009 | 1,122 | +17.7% | Form 10-Q (filed 2009-10-30) ↗ |
| Q2 2009 | Jun 30, 2009 | 1,040 | +9.3% | Form 10-Q (filed 2009-07-31) ↗ |
| Q1 2009 | Mar 31, 2009 | 947 | – | Form 10-Q (filed 2010-04-30) ↗ |
| Q4 2008 | Dec 31, 2008 | 1,059 | – | Form 10-K (filed 2010-02-22) ↗ |
| Q3 2008 | Sep 30, 2008 | 953 | – | Form 10-Q (filed 2009-10-30) ↗ |
| Q2 2008 | Jun 30, 2008 | 952 | – | Form 10-Q (filed 2009-07-31) ↗ |
Breakdown
What makes up total research and development expense ($m)
Cite this data
StockData. (2026). Eli Lilly Total research and development expense ($M) ($M), quarterly Q2 2008–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rd_exp_total
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.